PCa Commentary - nmCRPC and Androgen Receptor Inhibition: Enzalutamide, Apalutamide and Darolutamide
Автор: Grand Rounds in Urology
Загружено: 2022-11-08
Просмотров: 935
Описание:
In volume 171 of his monthly PCa Commentary series, Edward Weber, MD, looks at data on treatment regimens combining enzalutamide, apalutamide, or darolutamide with androgen deprivation in prolonging metastases-free and overall survival in men with nmCRPC who are at high risk for recurrence compared to ADT alone, as well as advantages of PSMA/PET over conventional imaging.
To read the Commentary in full, visit our website: https://grandroundsinurology.com/pca-...
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке: